Skip to main content

Insights on Pharmaceuticals & Medical Products

Report - McKinsey Global Institute

Prioritizing health: A prescription for prosperity

– Could 65 be the new 55? Each year, poor health takes a heavy societal and economic toll. Improving the health of the world’s population would add 10 healthy years in midlife—and much more.
Article

Winning against COVID-19: The implications for biopharma

– How companies act individually and collectively in the next few weeks and months will shape the outcome of the pandemic and the... reputation of the biopharma industry for decades to come.
Interactive - McKinsey Quarterly

Five Fifty: Science as unusual

– Innovations in biological science have quickened the global coronavirus response—and signal broader competitive disruptions for... business.
Survey

Survey: In the US, people say their use of masks may endure

– Americans are largely optimistic about COVID-19’s progression, according to a new survey, and their responses suggest that the... use of face masks will remain commonplace in the months ahead.
Survey

How US companies are planning for a safe return to the workplace

– In a new survey of 100 executives, respondents expect most employees to be working on-site by December. To do so, they are implementing... a range of interventions that could transform how people work.
Executive Briefing

COVID-19: Implications for business

– Our latest perspectives on the coronavirus outbreak, the twin threats to lives and livelihoods, and how organizations can prepare... for the next normal.
Podcast - McKinsey Global Institute

Programming life: An interview with Jennifer Doudna

– The co-discoverer of CRISPR-Cas9 speaks with partner Michael Chui about how genetics technology can expand coronavirus testing... and what the future holds for the Bio Revolution.
Report - McKinsey Global Institute

The Bio Revolution: Innovations transforming economies, societies, and our lives

– Advances in biological science could transform economies and societies, helping to tackle global challenges from climate change... to pandemics.
Article

COVID-19 implications for life sciences R&D: Recovery and the next normal

– COVID-19 has severely disrupted pharma and medtech R&D. Leaders should prepare along three horizons—safeguarding patients... and employees, adapting operations for a recovery, and building for the next normal.

Special Collection

The Rise of Health Technology

Health technology continues to push the boundaries of how healthcare is delivered and has the power to create breakthroughs in our understanding of disease. This collection of articles and interviews explores the evolving role of health technology in the life-sciences sector and implications for key stakeholders. Contact us to learn more about our work in this field.

Want to learn more about how we help clients in Pharmaceuticals & Medical Products?

More insights

Article - McKinsey Global Institute

How prioritizing health could help rebuild economies

– The COVID-19 pandemic has given the world a once-in-a-generation opportunity to advance broad-based health and prosperity.
Article

Not the last pandemic: Investing now to reimagine public-health systems

– The COVID-19 crisis reminds us how underprepared the world is to detect and respond to emerging infectious diseases. We must make... smart investments now to simultaneously navigate COVID-19 and prepare for future pandemics.
Article

Pharma operations: The path to recovery and the next normal

– Pharma operations leaders have increased their focus on network risk management, agile and transparent operations, and shaping... the workforce of the future in the post-COVID-19 path to recovery.
Article

How COVID-19 is reshaping China’s medtech industry

– With COVID-19 accelerating the underlying trends in China’s medtech industry, new business models are likely to emerge.
Article

How COVID-19 changes the game for biopharma in China

– Biopharmas should consider five areas as they deal with the crisis.
Article

Reimagining medtech for a COVID-19 world

– COVID-19 is creating unprecedented challenges for the medtech sector. Companies should consider stress-testing operating models... to strengthen crisis resilience and the longer-term path to recovery.
Article

COVID-19 and commercial pharma: Navigating an uneven recovery

– To respond best to the changes driven by the COVID-19 pandemic, pharma companies should consider reorienting their commercial... models to fit the needs of healthcare providers and patients better.
Article

Pharma operations: Creating the workforce of the future

– Reskilling employees to address talent gaps can help a company retain the bulk of its operations workers and empower them to take... advantage of a new world.
Article

Biopharma portfolio strategy in the era of cell and gene therapy

– Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment... opportunities and entry strategies will help guide their portfolio decisions.
Video

Accelerating progress in cancer care: Perspectives from six oncology leaders

– McKinsey recently spoke to industry leaders in oncology research and cancer care to ask about their vision of the future for oncology.
Article

The promise of digital therapeutics

– Investments in digital-therapeutics companies in the United States have grown, on average, by 40 percent a year over the past... seven years. What lies ahead for this fast-moving sector?
Sorry, we couldn't find any results. Try removing some filters.

More from this practice

McKinsey Cancer Center

The McKinsey Cancer Center helps life sciences organizations discover, develop, and distribute more effective medicines, deliver better care, and provide broader access to solutions that help patients and their families combat cancer.

Connect with our Pharmaceuticals & Medical Products Practice